Showing 1 - 3 results of 3 for search 'Jeroen A. D. M. de Roos', query time: 0.02s Refine Results
  1. 1
    Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use.

    Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. by Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jos de Man, Yoshinori Tanizawa, Yusuke Kawase, Kohichiro Yoshino, Rogier C Buijsman, Guido J R Zaman

    Published 2014-01-01
    Get full text
    Article
  2. 2
    Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

    Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. by Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jill A P Spijkers-Hagelstein, Judith R F de Vetter, Jos de Man, Rogier C Buijsman, Guido J R Zaman

    Published 2015-01-01
    Get full text
    Article
  3. 3
    Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

    Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 by Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman

    Published 2022-09-01
    Get full text
    Article

Search Tools: